title: Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease.
abstract: This review describes current considerations in the use of hydroxyurea for the management of sickle cell disease in the context of clinical severity. Randomized trials of hydroxyurea have generally enrolled subjects with increased severity based on frequent vaso-occlusive events. An exception was the BABY HUG study in infants which documented substantial benefit even for asymptomatic subjects. Increasing data indicate that hydroxyurea has a substantial effect on reducing mortality in both adults and children-perhaps the most compelling reason for advocating the drug's widespread use. Although the efficacy of hydroxyurea is mediated primarily through increased erythrocyte fetal hemoglobin and much has been learned about the genomic influences on fetal hemoglobin levels in sickle cell disease, our ability to predict the fetal hemoglobin response to hydroxyurea remains limited; much more work in this area is indicated. The review is concluded with the recommendations of the 2014 NIH Evidence-Based Management of Sickle Cell Disease Expert Panel Report.
authors.affiliation: Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA winfred.wang@stjude.org.
authors.forename: Winfred C
authors.initials: WC
authors.lastname: Wang
mesh_terms: D000755:Anemia, Sickle Cell / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D000986:Antisickling Agents / Q000627:therapeutic use*; D005319:Fetal Hemoglobin / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D011379:Prognosis; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000986:Antisickling Agents; D005319:Fetal Hemoglobin; D006918:Hydroxyurea
keywords: Sickle cell; clinical severity; hydroxurea; mortality; pharmacogenetics; prognosis